DSM-5 Substance Use Disorder Criteria
SUD is diagnosed when a substance causes clinically significant impairment. The same 11 criteria apply across most substances. Severity is determined by the number of criteria met in a 12-month period.
Impaired Control (1–4)
- Using more or for longer than intended
- Persistent desire / unsuccessful efforts to cut down
- Significant time spent obtaining, using, recovering
- Craving or strong urge to use
Social Impairment (5–7)
- Failure to fulfil major role obligations
- Continued use despite social/interpersonal problems
- Important activities given up or reduced
Risky Use (8–9)
- Recurrent use in physically hazardous situations
- Use despite knowledge of persistent physical/psychological problem caused by substance
Pharmacological (10–11)
- Tolerance (need for markedly increased amount for effect, or diminished effect with same amount)
- Withdrawal (characteristic syndrome, or using to relieve/avoid withdrawal)
Neurobiology of Addiction
Dopamine Reward Pathway
All addictive substances increase dopamine release in the mesolimbic pathway (VTA → nucleus accumbens). Natural rewards release 100–200% baseline dopamine; substances can cause 400–1000% surges, hijacking learning circuits.
Nucleus Accumbens
The "reward centre." Repeated substance exposure leads to downregulation of dopamine receptors → tolerance. The person needs more substance to achieve the same dopamine effect and experiences anhedonia without it.
Prefrontal Cortex Dysfunction
Chronic use impairs the PFC (executive control, impulse inhibition, decision-making). This explains why people continue using despite knowing consequences — it is a brain disease, not a moral failing.
Key Distinctions
| Term | Definition | Clinical Note |
|---|---|---|
| Tolerance | Reduced effect with repeated use; requires higher dose for same effect | Expected pharmacological adaptation; occurs without addiction |
| Physical Dependence | Physiological adaptation with withdrawal on cessation | Can occur with prescribed opioids/steroids; ≠ addiction |
| Addiction | Compulsive use despite harm; loss of control; craving | A brain disorder involving reward, motivation, memory circuits |
Screening Tools
CAGE Questionnaire (Alcohol)
- C — Have you ever felt you should Cut down on your drinking?
- A — Have people Annoyed you by criticising your drinking?
- G — Have you ever felt bad or Guilty about your drinking?
- E — Have you ever had a drink first thing in the morning (Eye-opener) to steady your nerves or get rid of a hangover?
AUDIT-C (Alcohol Use Disorders Identification Test — Concise)
3-question screen: (1) frequency of drinking, (2) drinks per occasion, (3) frequency of 6+ drinks. Score ≥3 women / ≥4 men = positive screen. Widely used in primary care.
DAST-10 (Drug Abuse Screening Test)
10 yes/no questions about drug use in the past year (excluding alcohol and tobacco). Score 0 = no problem; 1–2 = low level; 3–5 = moderate; 6–8 = substantial; 9–10 = severe.
Motivational Interviewing — OARS
| Skill | Purpose | Example |
|---|---|---|
| Open questions | Elicit patient's perspective | "What concerns do you have about your drinking?" |
| Affirmations | Build self-efficacy | "You've shown real strength making it this far." |
| Reflective listening | Demonstrate understanding; reduce resistance | Simple/complex reflections; avoid "but" |
| Summaries | Collect change talk; link ideas | Summarise ambivalence; invite correction |
Clinical Features of Chronic Alcohol Use Disorder
Stigmata of Chronic Liver Disease
- Spider naevi (>5 in distribution of SVC)
- Palmar erythema, Dupuytren's contracture
- Gynaecomastia, testicular atrophy
- Parotid enlargement, bilateral
- Leuconychia (Terry's nails), clubbing
- Caput medusae (portal hypertension)
- Hepatosplenomegaly, ascites, jaundice
Wernicke's Encephalopathy — COAT
CRITICAL: Administer IV thiamine (Pabrinex) BEFORE any glucose. Glucose without thiamine can precipitate or worsen Wernicke's → Korsakoff syndrome (irreversible anterograde amnesia).
Korsakoff Syndrome
Chronic consequence: anterograde amnesia + confabulation. Often irreversible. Thiamine stores depleted in 18–20 days of poor nutrition.
Alcohol Withdrawal — CIWA-Ar Overview
Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) assesses 10 domains. Reassess every 1–4 hours during acute withdrawal.
| Score | Severity | Management |
|---|---|---|
| <8 | Mild | Oral hydration, thiamine, monitoring; PRN benzodiazepine if score rises |
| 8–14 | Moderate | Scheduled + PRN benzodiazepine; IV access; frequent monitoring |
| ≥15 | Severe | IV benzodiazepine; ICU consideration; seizure precautions; crash cart nearby |
Benzodiazepine Protocol (Symptom-Triggered)
- Diazepam (Valium) 5–20 mg IV/PO every 1–2 h until CIWA-Ar <10 — long-acting; preferred for smooth coverage
- Lorazepam (Ativan) 1–4 mg IV/IM — preferred in liver disease (no active metabolites), or if rapid control needed
- Chlordiazepoxide fixed-dose tapering — commonly used in UK/community settings
Delirium Tremens (DTs)
Clinical Features
- Generalised tonic-clonic seizures
- Visual/tactile hallucinations (Lilliputian figures, insects crawling)
- Severe agitation, disorientation
- Autonomic instability: tachycardia, hypertension, hyperthermia, diaphoresis
- Global confusion, clouded consciousness
ICU Management
- IV lorazepam or IV diazepam — titrate to sedation; high doses may be required
- IV thiamine 500 mg TDS × 3 days then maintenance
- Antipsychotics (haloperidol) for persistent hallucinations — do NOT use alone (no anticonvulsant effect)
- Fluid/electrolyte replacement (hypomagnesaemia, hypokalaemia common)
- Continuous cardiac monitoring; treat hyperthermia
Pharmacotherapy for Alcohol Use Disorder
| Drug | Mechanism | Dosing | Key Counselling |
|---|---|---|---|
| Naltrexone | Opioid antagonist — blocks euphoria from alcohol; reduces craving | 50 mg/day PO or 380 mg IM monthly (Vivitrol) | Avoid opioids; hepatotoxic at high doses — LFT monitoring; do NOT use if opioid dependent |
| Acamprosate | Modulates GABA/glutamate — reduces protracted withdrawal symptoms / craving | 666 mg TDS (reduce in renal impairment) | Safe in liver disease; start after detox; takes 1 week to work; GI side effects |
| Disulfiram | Aldehyde dehydrogenase inhibitor → acetaldehyde accumulation with alcohol | 250–500 mg/day; supervised preferred | DISULFIRAM REACTION: flushing, vomiting, hypotension, tachycardia, dyspnoea with ANY alcohol (including mouthwash, sauces, perfume). Can be fatal in cardiac disease. |
Opioid Toxidrome & Naloxone Reversal
Additional Features
- Cyanosis, oxygen desaturation
- Bradycardia, hypotension
- Decreased bowel sounds
- Pulmonary oedema (especially heroin)
- Hypothermia, flaccid muscle tone
Naloxone (Narcan) Administration
- IV: 0.4–2 mg every 2–3 min; titrate to adequate respiration (not full reversal — avoid precipitated withdrawal)
- IM/SC: 0.4–0.8 mg — slower onset
- Intranasal: 4 mg — community use
- Duration: 30–90 min — shorter than most opioids; repeat dosing or infusion often required
- Monitor after reversal — re-sedation risk
Opioid Withdrawal — COWS Scale Overview
Clinical Opiate Withdrawal Scale (COWS). Unlike alcohol withdrawal, opioid withdrawal is NOT life-threatening in healthy adults — but is extremely distressing and a major trigger for relapse.
Withdrawal Timeline
| Opioid Type | Onset | Peak | Duration |
|---|---|---|---|
| Short-acting (heroin, morphine) | 6–24 h | 36–72 h | 5–7 days |
| Long-acting (methadone) | 36–48 h | 72–96 h | 2–3 weeks |
Signs & Symptoms
- Yawning, lacrimation, rhinorrhoea
- Diaphoresis, piloerection ("goosebumps")
- Anxiety, restlessness, irritability
- Muscle aches, bone pain, cramps
- Nausea, vomiting, diarrhoea
- Insomnia, dilated pupils (mydriasis)
- Tachycardia, hypertension, fever
- PAWS (Post-Acute Withdrawal Syndrome) — weeks/months
Methadone Maintenance Therapy (MMT) — Nursing
Supervised Consumption Protocol
- Observe patient swallow — check mouth for "cheeking"
- Confirm identity before dispensing (photo ID / DOB)
- Document dose, time, patient's response
- Takeaways only after demonstrated stability (weeks–months)
- Dose typically 60–120 mg/day (higher doses = better retention)
Critical Interactions
- QTc prolongation: Methadone can prolong QTc at high doses → Torsades de Pointes. Baseline and periodic ECG required, especially >100 mg/day or with other QTc-prolonging drugs.
- CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort) reduce methadone levels → withdrawal risk
- CYP3A4 inhibitors (fluconazole, erythromycin, grapefruit) increase methadone levels → overdose risk
- CNS depressants (benzos, alcohol) — additive respiratory depression — avoid combination
Methadone in Pregnancy
MMT is the standard of care in pregnancy — stabilises mother, prevents foetal withdrawal cycles from illicit use. Neonatal Abstinence Syndrome (NAS) is expected and manageable; untreated opioid use carries far greater risk. Breastfeeding generally compatible with stable low doses.
Buprenorphine/Naloxone (Suboxone)
Pharmacology
- Buprenorphine: Partial μ-opioid agonist + κ antagonist. High receptor affinity ("ceiling effect" on respiratory depression). Sublingual/buccal absorption.
- Naloxone component: Prevents IV misuse — if injected, precipitates withdrawal. Poorly absorbed sublingually.
- Typical doses: 8–24 mg/day sublingually
Induction Protocol — Critical
Starting too early: buprenorphine displaces full agonist from receptors → sudden severe withdrawal.
Advantages Over Methadone
- Safer in overdose (ceiling effect on respiratory depression)
- Can be prescribed by trained GPs (not only specialist centres)
- Less QTc risk; fewer drug interactions
- Monthly depot injection formulations available (Sublocade)
Tramadol Use Disorder — GCC Context
- Tramadol = weak opioid agonist + SNRI — dual dependence mechanism
- Readily available through informal networks; often adulterated
- Prescription surveillance programmes needed; some GCC countries have reclassified
- Withdrawal: mixed opioid + SNRI discontinuation syndrome
- Tapering should be gradual; consider treating as opioid withdrawal + SSRI discontinuation
Benzodiazepine Dependence
Diazepam Equivalence Conversion
| Drug | Equivalent to 5 mg Diazepam |
|---|---|
| Alprazolam (Xanax) | 0.25 mg |
| Lorazepam (Ativan) | 0.5 mg |
| Clonazepam (Rivotril) | 0.25–0.5 mg |
| Temazepam | 10 mg |
| Nitrazepam | 5 mg |
Tapering Protocol (Ashton Method)
- Convert to equivalent diazepam dose (long half-life = smoother taper)
- Reduce by approximately 10% of current dose every 1–2 weeks
- Slow the taper if significant withdrawal symptoms emerge
- Typical duration: weeks to months depending on dose and duration of use
Stimulant Use — Cocaine & Amphetamines
Acute Intoxication
- Euphoria, increased energy, decreased appetite
- Tachycardia, hypertension, hyperthermia
- Dilated pupils, diaphoresis
- Cardiac: MI, arrhythmias (even in young without CAD)
- Stroke (haemorrhagic or ischaemic)
- Serotonin syndrome with other serotonergic drugs
Treatment
- No specific pharmacotherapy for stimulant use disorder
- Acute: benzodiazepines for agitation/seizures; cooling for hyperthermia
- Avoid beta-blockers in cocaine toxicity (unopposed alpha → hypertensive crisis)
- Psychological: CBT, contingency management (most evidence-based)
- Crystal methamphetamine ("shabu", "ice") increasingly prevalent in GCC — prolonged psychosis common
Cannabis Use Disorder
Cannabis Use Disorder (DSM-5)
11% of users develop CUD. Daily users: 25–50%. Withdrawal syndrome: irritability, insomnia, decreased appetite, anxiety — mild, peaks day 2–6, resolves in 1–2 weeks.
Cannabis-Induced Psychosis
High-potency THC products significantly increase psychosis risk, particularly in adolescents and those with family history of schizophrenia. May unmask latent schizophrenia.
Cannabinoid Hyperemesis Syndrome (CHS)
Often misdiagnosed as cyclic vomiting syndrome. Antiemetics largely ineffective. Capsaicin cream to abdomen may provide temporary relief. Only cure: cannabis cessation.
Khat (Catha edulis)
- Fresh leaves chewed for cathinone (active stimulant, similar to amphetamine)
- Effects: euphoria, increased alertness, decreased appetite, loquaciousness
- Chronic use: insomnia, hypertension, periodontal disease, malnutrition, psychosis
- Social: chewing sessions last 3–6 hours; significant social/cultural role
- Withdrawal: mild — fatigue, dysphoria, increased appetite, insomnia
- Culturally sensitive assessment essential — avoid stigmatising approach
Inhalant Use (Volatile Substances)
- Substances: solvents (glue, petrol, paint thinner), aerosols (deodorant, hairspray), gases (nitrous oxide, butane)
- Acute: euphoria, dizziness, slurred speech, disorientation (minutes)
- Chronic: white matter damage, cerebellar ataxia, renal tubular acidosis, peripheral neuropathy
- Management: supportive; avoid adrenaline (risk of arrhythmia); treat acidosis
Tobacco & Nicotine Dependence
GCC has very high smoking rates, particularly among males. Water pipe (shisha/hookah) smoking is extremely prevalent and culturally normalised, with a common misconception that it is safer than cigarettes — it is not.
NRT (Nicotine Replacement Therapy)
Patches, gum, lozenge, inhaler. Doubles quit rates vs placebo. Combine patch (background) + short-acting (breakthrough) for best results.
Varenicline (Champix/Chantix)
Partial nicotinic receptor agonist. Most effective pharmacotherapy. Neuropsychiatric warning: monitor for mood changes. Reduce dose in severe renal impairment.
Bupropion (Zyban)
NDRI antidepressant. Contraindicated in seizure disorder, eating disorders. Lower efficacy than varenicline but useful in patients with depression.
Harm Reduction Principles
Harm reduction accepts that some individuals will continue using substances and focuses on reducing the negative consequences of use without requiring abstinence as a precondition for receiving care.
Core Principles
- Non-judgemental, non-coercive engagement
- Any positive change is valued
- People are experts in their own lives
- Addresses immediate, concrete needs
- Reduces stigma and increases help-seeking
GCC Limitations
- Needle/syringe exchange: not available (legal barriers)
- Take-home naloxone: very limited access
- Drug consumption rooms: not available
- Harm reduction messages may conflict with zero-tolerance legal framework
- Nurses navigate tension between clinical duty and legal environment
Brief Intervention — FRAMES
| Component | Description | Example Phrase |
|---|---|---|
| Feedback | Personalised risk assessment results | "Your AUDIT score suggests hazardous drinking — here's what that means for your health..." |
| Responsibility | Emphasise patient's autonomy and responsibility for change | "Ultimately, this is your decision — I'm here to support whatever you choose." |
| Advice | Clear advice to change, non-prescriptive | "I strongly recommend reducing your alcohol intake — here are some ways to do that." |
| Menu | Range of options offered | "There are several approaches: cut-down goals, counselling, medication, or a combination." |
| Empathy | Warm, reflective, non-confrontational style | "I can hear that this has been really difficult for you." |
| Self-efficacy | Reinforce belief in ability to change | "You've made difficult changes before — I believe you can do this." |
Brief interventions (5–20 minutes) are evidence-based and cost-effective, especially for alcohol. Even brief advice from a nurse significantly increases quit and reduction rates.
Recovery Support — 12-Step & SMART
12-Step (AA/NA)
Alcoholics Anonymous / Narcotics Anonymous. Mutual aid, peer support, spiritual framework. GCC limitations: predominantly designed for Western Christian context; limited availability, especially for non-English speakers and non-Muslims. Concept of "higher power" can be adapted to Islamic framework in some programmes.
SMART Recovery
Self-Management and Recovery Training. Evidence-based, secular, CBT-based approach. 4-point programme: building and maintaining motivation; coping with urges; managing thoughts/feelings/behaviours; living a balanced life. Available online — accessible in GCC context.
Dual Diagnosis — Co-occurring Mental Illness
Common Co-occurring Conditions
- Depression + Alcohol: Most common — alcohol is a CNS depressant; often used to self-medicate but worsens depression long-term
- Anxiety disorders + Benzodiazepines/Alcohol: Temporary relief → dependence → rebound anxiety
- PTSD + Alcohol/Cannabis: Self-medication of hyperarousal and nightmares
- Schizophrenia + Cannabis/Stimulants: Worsens psychosis, reduces antipsychotic efficacy
- ADHD + Stimulants: Untreated ADHD is a risk factor for SUD; stimulant SUD may represent self-medication
Nursing Approach
Screen all substance use patients for mental illness and vice versa. Avoid treating sequentially (abstinence first, then mental health) — this approach fails. Address both simultaneously with an integrated team.
Inpatient Detoxification Nursing
Assessment on Admission
- Full substance use history (substances, amounts, frequency, last use)
- Previous withdrawal history (seizures, DTs — high predictor of future severity)
- Baseline vitals including ECG where indicated
- Baseline CIWA-Ar / COWS score
- Mental health screening (PHQ-9, GAD-7, trauma history)
Ongoing Nursing Responsibilities
- Hourly observations during acute withdrawal; 4-hourly when stable
- CIWA-Ar / COWS reassessment before PRN medication
- Nutritional support, hydration, vitamin supplementation (thiamine, folate, B12)
- Seizure precautions if high risk; suction + O₂ available
- Therapeutic engagement — empathy, reduce shame, motivational approach
- Discharge planning: link to community services, prescriptions for MAT
Legal Framework — Alcohol in GCC
| Country | Alcohol Status | Notes |
|---|---|---|
| UAE | Legal (licensed) | Licensed hotels/restaurants; non-Muslims only; personal licence required in Dubai/Abu Dhabi. Age 21+. |
| Qatar | Legal (restricted) | Qatar Distribution Company; licensed hotels; non-Muslims; expanded for 2022 World Cup. |
| Bahrain | Legal (licensed) | Most liberal GCC country; licensed premises; non-Muslims generally permitted. |
| Oman | Legal (licensed) | Licensed hotels and shops; non-Muslims; consumption in public prohibited. |
| Saudi Arabia | Prohibited | Total prohibition. No licensed premises. Severe penalties including flogging (historically), deportation, imprisonment. |
| Kuwait | Prohibited | Total prohibition since 1964. No exceptions. Penalties include imprisonment and deportation. |
Drug Laws in GCC — Nurse Legal Obligations
Penalties Overview
- Possession: Imprisonment (months to years), deportation, fines
- Trafficking: Life imprisonment or death penalty in UAE, Saudi Arabia, Qatar, Kuwait
- Zero tolerance — no distinction between recreational and dependent use in many cases
- Drug testing may be mandatory (employment, accident, clinical admission)
Nursing Legal Obligations
- Mandatory reporting laws vary by country — know your country's specific requirements
- Clinical confidentiality vs. legal reporting: consult hospital legal/ethics team
- Nurses do NOT generally have immunity from prosecution if they facilitate drug use
- Document all clinical findings accurately and professionally
- Non-judgmental care remains a professional duty regardless of legal context
Drug Courts — Shifting Paradigm
GCC countries are increasingly developing drug court systems that offer rehabilitation as an alternative to incarceration for possession/use offences. UAE, Qatar, and Saudi Arabia have implemented programmes emphasising treatment over punishment — a significant shift from purely punitive approaches.
Cultural Factors Affecting Assessment
Alcohol Under-reporting
Given cultural, religious, and legal stigma, patients in GCC may significantly under-report alcohol use. Nurses should use objective markers alongside screening tools:
- Elevated GGT, MCV, AST:ALT ratio >2:1, elevated urate
- CDT (carbohydrate-deficient transferrin) — specific marker for heavy alcohol use
- Clinical signs of liver disease or withdrawal
Duty-Free Alcohol
A significant pattern in GCC: expatriates and returning residents purchase alcohol through duty-free allowances for home consumption. This enables high-volume home drinking that avoids public scrutiny, making assessment more difficult.
Cultural Shame & Help-Seeking
- Strong cultural and family shame around substance use disorders
- Families may conceal addiction from wider community
- Religious frameworks may frame addiction as moral weakness rather than illness
- Approach: frame treatment as restoring health and family well-being; use patient's own values
Expat Vulnerability & Islamic Recovery
Expatriate Risk Factors
- Social isolation; separation from family networks
- Cultural dislocation and identity stress
- Work-related stress in demanding industries (construction, hospitality)
- Low-wage workers: limited leisure options, overcrowded accommodation
- Language barriers limiting access to services
- Fear of deportation preventing help-seeking
Islamic Addiction Treatment
- Faith-based rehabilitation integrating Islamic principles
- Framing recovery as a religious duty (protect the mind — one of Islam's 5 necessities)
- Quran recitation, prayer, and spiritual community as protective factors
- Imam counselling as adjunct to clinical treatment
- Some GCC hospitals integrate Islamic chaplaincy into addiction services
Private Addiction Treatment Centres in GCC
- The Cabin Dubai — addiction treatment centre based on therapeutic community model
- Priory-concept programmes — evidence-based residential treatment adapted for GCC market
- Government-run rehabilitation: National Rehabilitation Centre (UAE), NCAAA (Saudi Arabia)
- Challenges: cost, stigma, lack of anonymity, limited Arabic-language services
CIWA-Ar — Alcohol Withdrawal Severity Score
Clinical Institute Withdrawal Assessment for Alcohol, Revised. Assess each domain and select the best description. Reassess every 1–4 hours.
COWS — Clinical Opiate Withdrawal Scale
Assess 11 items. Total score 0–48. Used for monitoring opioid withdrawal severity and guiding treatment decisions (including buprenorphine induction timing).
Practice MCQs — Substance Use Disorder
Select an answer to reveal instant feedback with explanation.